The Niche

Comments on two previous posts

Lee Buckler has pointed out on my business round-up that the merger between reagents-and-animal-cells company Stem Cell Sciences in the UK and the cell therapy company StemCells in California creates a single company with near-term, medium-term and long-term sources of revenue. That makes sense to me, even though the differences in technologies and the geography seem hard to manage. Also, he just posted a very comprehensive round-up himself. You can see them here. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE